shutterstock_1492661771_ricochet64

ricochet64 / Shutterstock.com

26 June 2020Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More features

President Trump 2.0: Five major areas to watch

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court